Loading…
Loading…
EMED does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EMED and 80,000+ other tickers.
See exactly how EMED's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EMED and 80,000+ other tickers.
Electromedical Technologies, Inc. operates within the U.S. market, specializing in the creation and distribution of bioelectronic medical devices specifically designed for pain management. The company's primary product is WellnessPro Plus, a prescription-based bioelectronic therapy tool utilized by both individual users and healthcare professionals to mitigate various forms of discomfort, including both persistent (chronic) and sudden (acute) pain. Established in 2002, the firm is headquartered in Scottsdale, Arizona.
Electromedical Technologies (OTC: EMED) outlines key financial restructuring milestones, upcoming product updates, and new strategic partnerships to drive sustainable growth in the pain management market. SCOTTSDALE, ARIZONA / ACCESS Newswire / August 6, 2025 / Electromedical Technologies, Inc. ("Electromedical" or the "Company") (OTC:EMED), a developer and manufacturer of FDA-cleared electrotherapy devices for pain management, today issued a mid-year update reflecting key steps taken to strengthen its financial position and advance core initiatives.
Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain management and wellness technology. SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / Electromedical Technologies, Inc. (OTC PINK:EMED) - Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain management and wellness technology.
Electromedical (EMED), a Leader in Bioelectronic Medical Devices, Updates Shareholders on Recent Achievements and Strategic Advancements SCOTTSDALE, AZ / ACCESSWIRE / August 8, 2024 / Electromedical (OTC PINK:EMED), a leading innovator in bioelectronic medical devices, is pleased to provide an update to its shareholders, highlighting significant recent achievements and strategic advancements. EMED Logo Sales Growth: 17% increase in revenue in year ended 2023 over year ended in 2022.
Electromedical Announces $1.36M Net Proceeds from Building Sale to Fund WellnessPro Infinity™ Launch and Convertible Note Retirement SCOTTSDALE, Ariz., March 22, 2023 /PRNewswire/ — Electromedical Technologies, Inc. (OTCQB: EMED) (“Electromedical” or the “Company”), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, […]...
SCOTTSDALE, Ariz., Sept. 30, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it has passed the ISO 13485:2016 recertification audit for Medical Device and Quality Management Systems.